Primary Objective: To confirm the findings of several small studies conducted in the southeastern United States showing hypersensitivity infusion reaction (HIR) rates as high as 22% with the monoclonal antibody, cetuximab. Although well known for a risk of HIRs, early clinical studies showed much lower reaction rates of 3%.
Identifer | oai:union.ndltd.org:ETSU/oai:dc.etsu.edu:etsu-works-3451 |
Date | 01 March 2012 |
Creators | Angles, M., Bossaer, John B. |
Publisher | Digital Commons @ East Tennessee State University |
Source Sets | East Tennessee State University |
Detected Language | English |
Type | text |
Source | ETSU Faculty Works |
Page generated in 0.0018 seconds